Alnylam Pharmaceuticalsvs.United Therapeutics
ALNY vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 1.7× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (18.0 vs 69.1); year to date, United Therapeutics leads (+12.3% vs −24.9%).
Side by side
| ALNY | UTHR | |
|---|---|---|
| Market cap | $39.9B | $23.2B |
| Price | $298.76 | $547.06 |
| Today | −4.5% | −1.0% |
| Return YTD | −24.9% | +12.3% |
| Return 1Y | −7.4% | +82.3% |
| P/E | 69.1 | 18.0 |
| P/S | 9.3 | 7.3 |
| P/B | 37.1 | 3.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →United TherapeuticsUTHR
Biopharma in pulmonary hypertension and organ manufacturing (xenotransplantation).
Full UTHR profile →More comparisons in Biotech & innovation
See where ALNY and UTHR sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →